Skip to main content

Table 1 Characteristics of the study participants

From: Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions

Characteristic No. of patients, N = 146
SLE, no. (%) 121 (82.80)
RA, no. (%) 25 (17.20)
Age, mean ± SD years 42.27 ± 14.13
Female, no. (%) 139 (95.20)
Weight, mean ± SD kg 56.89 ± 9.21
Duration of HCQ treatment, mean ± SD months 51.70 ± 46.50
HCQ dose, mean ± SD mg/day 255.48 ± 77.93
HCQ dose, mean ± SD mg/kg/day 4.58 ± 1.50
Daily prednisolone dose, mean ± SD mg 4.77 ± 4.33
DSA28 score, mean ± SD 2.16 ± 0.41
SLEDAI score, mean ± SD 0.89 ± 1.81
[HCQ], mean ± SD ng/ml 838.10 ± 522.00
[DHCQ], mean ± SD ng/ml 582.80 ± 363.90
[DCQ], mean ± SD ng/ml 346.90 ± 205.30
[BDCQ], mean ± SD ng/ml 56.00 ± 39.30
ADR, no. (%)
Abnormal renal function 21 (14.30)
Abnormal liver function 11 (7.50)
Ophthalmic ADRs 20 (13.70)
Skin and mucous membrane ADRs 15 (10.30)
  1. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ADRs, Adverse drug reactions; Disease activity score 28, DAS28; [HCQ], HCQ concentration; [DHCQ], Desethyl hydroxychloroquine concentration; [DCQ], Desethyl chloroquine concentration; [BDCQ], Bisdesethyl chloroquine concentration